Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01598025 · ClinicalTrials.gov registry record · NA
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT01598025: Clinical Trial NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01598025 is a NA study that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01598025, a NA study, was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
Approximately 30% of patients who are candidates for bone marrow transplants do not have an HLA-matched, or close to matched, donor available. For this reason, doctors have been testing ways to make transplants from HLA-partially matched donors as safe and effective as transplants from HLA-matched donors. This study is being done to test the safety and the treatment results of a specific kind of transplant. In this transplant, blood from two donors will be used. Each donor will share one half of your HLA type. Blood from both donors will be transplanted at the same time.
Interventions
- DRUG fludarabine phosphate
- DRUG melphalan
- DRUG thiotepa
- BIOLOGICAL anti-thymocyte globulin
- RADIATION total-body irradiation (TBI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2012-05-02 |
| Est. Completion | 2017-10-16 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01598025
The ClinicalTrials.gov registry entry for NCT01598025 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which fludarabine phosphate is the first listed.
NCT01598025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01598025 about?
NCT01598025 is a clinical study titled "Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor". Approximately 30% of patients who are candidates for bone marrow transplants do not have an HLA-matched, or close to matched, donor available. For this reason, doctors have been testing ways to make transplants from HLA-partially matched donors as safe and effective as transplants from HLA-matched d...
What is the current status of trial NCT01598025?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2012-05-02. Estimated completion is 2017-10-16.
What interventions are being tested in trial NCT01598025?
The interventions under investigation include: fludarabine phosphate (DRUG), melphalan (DRUG), thiotepa (DRUG), anti-thymocyte globulin (BIOLOGICAL), total-body irradiation (TBI) (RADIATION).
Who is sponsoring clinical trial NCT01598025?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.